Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Outstanding (2016 - 2025)

Zevra Therapeutics' Shares Outstanding history spans 11 years, with the latest figure at $58.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 5.6% year-over-year to $58.3 million; the TTM value through Dec 2025 reached $58.3 million, up 5.6%, while the annual FY2025 figure was $58.3 million, 5.6% up from the prior year.
  • Shares Outstanding reached $56.9 million in Q4 2025 per ZVRA's latest filing, down from $57.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $57.8 million in Q3 2025 to a low of $28.5 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $42.0 million, with a median of $36.6 million recorded in 2023.
  • The largest YoY upside for Shares Outstanding was 671.5% in 2021 against a maximum downside of 51.3% in 2021.
  • A 5-year view of Shares Outstanding shows it stood at $35.0 million in 2021, then fell by 1.33% to $34.5 million in 2022, then increased by 20.25% to $41.5 million in 2023, then skyrocketed by 33.01% to $55.2 million in 2024, then increased by 5.6% to $58.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Shares Outstanding are $58.3 million (Q4 2025), $56.2 million (Q3 2025), and $55.1 million (Q2 2025).